CD4 cell response to interval therapy with natalizumab

Natalizumab treatment alters peripheral CD4 cells counts in multiple sclerosis (MS) patients, providing a way to monitor the pharmacodynamic effects of the drug. The study was undertaken to assess whether CD4 cell counts correlate with different phases of natalizumab treatment of relapsing MS patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Berkovich, Regina, Togasaki, Daniel M, Cen, Steven Y, Steinman, Lawrence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435710/
https://www.ncbi.nlm.nih.gov/pubmed/26000328
http://dx.doi.org/10.1002/acn3.190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435710/
https://www.ncbi.nlm.nih.gov/pubmed/26000328
http://dx.doi.org/10.1002/acn3.190

Ejemplares similares